Skip to main content
SpringerLink
Log in
Book cover

Portal Hypertension VI pp 99–104Cite as

Antiviral Treatments and Residual Risk of Hepatic Decompensation

  • Conference paper

  • 1062 Accesses

Abstract

Chronic viral infections with hepatitis B as well as hepatitis C virus can be controlled or cured with great certainty today. Only delta superinfection of chronic hepatitis B patients still remains a problem with poor treatment options. Virological control or cure of noncirrhotic as well as compensated cirrhotic patients with any kind of treatment including interferon-containing regimens prevents future decompensation in almost all patients. Virological control using nucleotide analogues in hepatitis B patients also prevents decompensation effectively, while using interferon-based regimens in decompensated patients improves the overall outcome but carries a significant risk of deterioration and death, in particular when used in combination with first-generation protease inhibitors. All oral direct-acting antivirals (DAAs) have shown promising preliminary results even in a limited number of decompensated patients. But more data are needed to evaluate the long-term outcome of cure of decompensated HCV-cirrhotic patients with different DAA regimens to guide individualized treatment decisions, including when and how to treat patients already on the liver transplant waiting list.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. World Health Organization (2015) Global Health Sector Strategy on viral hepatitis, 2016–2021 (Draft for consultation). WHO, Geneva

    Google Scholar 

  2. Cowie BC, Allard N, MacLachlan JH (2014) European REsponses in Focus: comparing viral hepatitis and HIV related deaths in Europe 1990–2010 in the Global Burden of Disease Study 2010. J Hepatol 60(Suppl):O86

    Google Scholar 

  3. Torresi J, Locarnini S (2000) Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 118:S83–S103

    Article  CAS  PubMed  Google Scholar 

  4. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez Tapias J, Almasio P, Christensen E et al (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21:77–82

    CAS  PubMed  Google Scholar 

  5. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678–686

    Article  PubMed  Google Scholar 

  6. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J et al (2010) Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747–1754

    Article  PubMed  Google Scholar 

  7. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345:41–52

    Article  CAS  PubMed  Google Scholar 

  8. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC et al (2009) Effect of HCV RNA suppression during peginterferon Alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 137:1986–1994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM et al (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359:2429–2441

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E et al (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682–2695

    Article  CAS  PubMed  Google Scholar 

  11. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM et al (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206–1217

    Article  CAS  PubMed  Google Scholar 

  12. Viganò M, Invernizzi F, Lampertico P (2015) Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? Liver Int 35:107–113

    Article  PubMed  Google Scholar 

  13. Vlachogiannakos J, Papatheodoridis GV (2015) Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int 35:100–106

    Article  CAS  PubMed  Google Scholar 

  14. van der Meer AJ, Veldt BJ, Feld JJ et al (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis. JAMA 308:2584–2593

    Article  PubMed  Google Scholar 

  15. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R et al (2010) Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51:2069–2076

    Article  CAS  PubMed  Google Scholar 

  16. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L et al (2007) Peginterferon Alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 46:206–212

    Article  CAS  PubMed  Google Scholar 

  17. Iacobellis A, Perri F, Valvano MR, Caruso N, Niro GA, Andriulli A (2011) Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 9:249–253

    Article  PubMed  Google Scholar 

  18. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M et al (2011) Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 9:602–608.e601

    Article  PubMed  Google Scholar 

  19. Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V et al (2014) Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147:132–142.e132

    Article  CAS  PubMed  Google Scholar 

  20. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML et al (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973–1982

    Article  PubMed  Google Scholar 

  21. Flamm S, Everson G, Charlton MR, Denning J, Afterburn S, Brandt-Sarif T, Pang PS et al (2014) Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective multicenter study. Hepatology 60(Suppl):A239

    Google Scholar 

  22. Afdhal N, Everson G, Calleja JL, McCaughan GW, Symonds W, Denning J, McNair L et al (2014) Sofosbuvir and ribavirin for the treatment chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 60(Suppl):O68

    Google Scholar 

  23. Manns M, Forns X, Samuel D, Denning J, Arterburn S, Brandt-Sarif T, Dvory-Sobol H et al (2015) Ledipasvir/Sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective Solar 2 trial. J Hepatol 62(Suppl):G02

    Google Scholar 

  24. Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG (2015) Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 60:1031–1035

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Gastroenterologie and Hepatologie, AKH and Medical University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria

    Markus Peck-Radosavljevic MD

Authors
  1. Markus Peck-Radosavljevic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Peck-Radosavljevic MD .

Editor information

Editors and Affiliations

  1. Gastroenterology Unit, Luigi Sacco University Hospital, Milan, Italy

    Roberto de Franchis

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this paper

Cite this paper

Peck-Radosavljevic, M. (2016). Antiviral Treatments and Residual Risk of Hepatic Decompensation. In: de Franchis, R. (eds) Portal Hypertension VI. Springer, Cham. https://doi.org/10.1007/978-3-319-23018-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23018-4_12

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23017-7

  • Online ISBN: 978-3-319-23018-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation